RXST Stock Price, RxSight, Inc. Quote, Chart

Market Summary

USD60.65-1.61

Delayed

-2.59%

RXST Alerts

2 major insider sales recently.

Big jump in Revenue (Y/Y)
Losses in recent quarter

RXST Stock Price

View Fullscreen

RXST RSI Chart

RXST Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-50.7

Price/Sales (Trailing)

22.31

EV/EBITDA

-57.85

Price/Free Cashflow

-57.59

RXST Price/Sales (Trailing)

RXST Profitability

EBT Margin

-43.98%

Return on Equity

-27.14%

Return on Assets

-24.29%

Free Cashflow Yield

-1.74%

RXST Fundamentals

RXST Revenue

Revenue (TTM)

101.1M

Rev. Growth (Yr)

68.75%

Rev. Growth (Qtr)

3.26%

RXST Earnings

Earnings (TTM)

-44.5M

Earnings Growth (Yr)

31.12%

Earnings Growth (Qtr)

0.84%

Breaking Down RXST Revenue

Last 7 days

2.3%

Last 30 days

14.8%

Last 90 days

10.4%

Trailing 12 Months

147.4%

How does RXST drawdown profile look like?

RXST Financial Health

Current Ratio

9.2

RXST Investor Care

Shares Dilution (1Y)

9.46%

Diluted EPS (TTM)

-1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	101.1M	0	0	0
2023	57.6M	67.0M	76.6M	89.1M
2022	28.1M	34.5M	41.3M	49.0M
2021	16.7M	18.6M	20.6M	22.6M
2020	0	0	0	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of RxSight, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	kurtz ronald m md	sold	-2,405,870	60.1468	-40,000	president & ceo
May 01, 2024	thunen shelley b	acquired	159,836	15.5983	10,247	chief financial officer
May 01, 2024	thunen shelley b	sold	-526,913	52.6913	-10,000	chief financial officer
Apr 01, 2024	thunen shelley b	sold	-997,946	49.8973	-20,000	chief financial officer
Mar 01, 2024	thunen shelley b	sold	-563,726	56.3726	-10,000	chief financial officer
Mar 01, 2024	thunen shelley b	acquired	155,983	15.5983	10,000	chief financial officer
Feb 16, 2024	goldshleger ilya	acquired	230,400	23.04	10,000	chief operating officer
Feb 16, 2024	goldshleger ilya	sold	-555,000	55.5	-10,000	chief operating officer
Feb 15, 2024	goldshleger ilya	sold	-535,000	53.5	-10,000	chief operating officer
Feb 15, 2024	goldshleger ilya	acquired	230,400	23.04	10,000	chief operating officer

Which funds bought or sold RXST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	6.84	374,480	1,395,340	-%
May 16, 2024	COMERICA BANK	added	2.88	6,638	27,598	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-70.45	-1,722,960	1,047,230	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	reduced	-68.76	-760,713	506,464	0.09%
May 15, 2024	Centiva Capital, LP	new	-	450,087	450,087	0.01%
May 15, 2024	Alpha DNA Investment Management LLC	reduced	-10.51	76,903	607,716	0.22%
May 15, 2024	BARCLAYS PLC	reduced	-41.42	-440,000	1,318,000	-%
May 15, 2024	Point72 Europe (London) LLP	new	-	4,418,450	4,418,450	0.39%
May 15, 2024	Walleye Capital LLC	reduced	-72.72	-2,382,350	1,277,170	-%
May 15, 2024	Parkman Healthcare Partners LLC	reduced	-19.61	587,793	21,273,200	2.61%

Are Funds Buying or Selling RXST?

Are funds buying RXST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RXST

No. of Funds

Unveiling RxSight, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.5%	3,404,285	SC 13G/A
Feb 14, 2024	lord, abbett & co. llc	5.51%	1,977,000	SC 13G
Feb 12, 2024	artisan partners limited partnership	6.7%	2,395,672	SC 13G
Jan 29, 2024	blackrock inc.	5.8%	2,076,470	SC 13G
Aug 18, 2023	longitude capital partners ii, llc	2.8%	994,313	SC 13D/A
Jun 05, 2023	longitude capital partners ii, llc	4.4%	1,491,463	SC 13D/A
Feb 14, 2023	orbimed advisors llc	3.3%	923,733	SC 13G/A
Feb 14, 2022	wolfen richard m.	6.7%	1,827,349	SC 13G
Feb 14, 2022	rxsight i, llc	7.60%	2,016,778	SC 13G
Feb 14, 2022	tamer anthony	7.34%	2,010,037	SC 13G

Recent SEC filings of RxSight, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	SD	SD
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	8-K	Current Report
May 08, 2024	424B5	Prospectus Filed
May 08, 2024	S-3ASR	S-3ASR
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	4	Insider Trading
May 06, 2024	8-K	Current Report
May 03, 2024	144	Notice of Insider Sale Intent
May 02, 2024	4	Insider Trading

Peers (Alternatives to RxSight, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

RxSight, Inc. News

Latest updates

RxSight, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	3.3%	29,512,000	28,579,500	22,199,000	20,810,000	17,489,000	16,088,000	12,615,000	11,360,000	8,942,000	8,426,000	5,786,000	4,897,000	3,484,000	3,827,000	4,170,000	2,706,000
Gross Profit	17.2%	20,685,000	17,653,500	13,731,000	12,015,000	10,366,000	7,422,500	5,356,000	4,788,000	3,761,000	2,869,000	1,341,000	-812,000	1,119,000	-	720,000	-474,000
Operating Expenses	10.0%	31,355,000	28,505,000	26,243,000	25,640,000	23,463,000	22,412,500	21,314,000	20,580,000	20,339,000	17,532,000	14,453,000	13,065,000	12,254,000	-	9,626,000	8,333,000
S&GA Expenses	10.2%	23,324,000	21,164,000	19,142,000	18,239,000	16,255,000	15,731,000	14,926,000	14,388,000	13,620,000	11,616,000	9,076,000	6,502,000	5,611,000	-	3,825,000	3,249,000
R&D Expenses	9.4%	8,031,000	7,341,000	7,101,000	7,401,000	7,208,000	6,681,500	6,388,000	6,192,000	6,719,000	5,916,000	5,377,000	6,563,000	6,643,000	-	5,801,000	5,084,000
EBITDA Margin	17.8%	-0.38	-0.46	-0.60	-0.74	-0.92	-1.18	-1.41	-1.57	-1.83	-1.82	1.55	1.72	-	-	-	-
Interest Expenses	71.4%	6,000	3,500	230,000	1,568,000	1,507,000	1,451,000	1,299,000	1,136,000	1,060,000	1,079,000	1,079,000	826,000	698,000	-	3,000	4,000
Income Taxes	150.0%	9,000	-18,000	12,000	26,000	-	5,000	-	-	4,000	2,000	-4,000	3,000	7,000	-	8,000	40,000
Earnings Before Taxes	1.1%	-9,091,000	-9,195,000	-12,403,000	-13,778,000	-13,212,000	-15,605,000	-16,818,000	-16,732,000	-17,592,000	-15,731,500	-12,677,000	-13,474,000	-6,798,000	-	30,672,000	-12,842,000
EBT Margin	19.4%	-0.44	-0.55	-0.72	-0.89	-1.08	-1.36	-1.62	-1.82	-2.12	-2.15	1.34	1.48	-	-	-	-
Net Income	0.8%	-9,100,000	-9,177,000	-12,415,000	-13,804,000	-13,212,000	-15,610,000	-16,818,000	-16,732,000	-17,596,000	-15,733,500	-12,673,000	-13,477,000	-6,805,000	26,295,000	30,664,000	-12,882,000
Net Income Margin	19.3%	-0.44	-0.55	-0.72	-0.89	-1.08	-1.36	-1.62	-1.82	-2.12	-2.16	-0.32	1.97	-	-	-	-
Free Cashflow	-14.0%	-11,276,000	-9,892,000	-8,635,000	-9,369,000	-18,511,000	-14,216,000	-15,768,000	-15,904,000	-15,355,000	-9,087,000	-14,009,000	-12,802,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	0.3%	183	183	182	195	203	150	156	167	177	193	204	95.00	101
Current Assets	0.1%	169	168	168	180	188	135	139	150	161	176	186	76.00	82.00
Cash Equivalents	244.2%	33.00	10.00	10.00	9.00	11.00	12.00	10.00	25.00	25.00	25.00	69.00	42.00	14.00
Inventory	7.3%	19.00	17.00	19.00	18.00	18.00	15.00	15.00	12.00	8.00	8.00	9.00	9.00	8.00
Net PPE	7.2%	12.00	11.00	10.00	11.00	10.00	10.00	11.00	11.00	11.00	11.00	12.00	13.00	13.00
Liabilities	-13.3%	19.00	22.00	20.00	38.00	58.00	60.00	60.00	57.00	54.00	54.00	53.00	55.00	45.00
Current Liabilities	-12.3%	18.00	21.00	19.00	17.00	15.00	17.00	16.00	13.00	11.00	11.00	9.00	11.00	12.00
Long Term Debt	-	-	-	-	20.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00	24.00
Shareholder's Equity	2.2%	164	160	161	157	145	90.00	96.00	110	123	138	151	-	-
Retained Earnings	-1.5%	-603	-594	-585	-573	-559	-546	-530	-513	-496	-479	-463	-450	-430
Additional Paid-In Capital	1.7%	768	755	747	730	704	636	626	624	620	618	614	138	-
Shares Outstanding	2.8%	37.00	36.00	36.00	35.00	34.00	28.00	28.00	28.00	27.00	27.00	19.00	4.00	-
Float	-	-	-	-	869	-	-	-	310	-	236	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-12.1%	-9,309	-8,301	-7,982	-7,546	-17,764	-13,854	-15,188	-14,823	-14,985	-8,722	-13,755	-11,979	-10,252	-	-	-
Share Based Compensation	6.1%	4,696	4,425	4,071	3,955	3,295	2,962	2,882	2,904	2,649	2,917	2,013	1,406	1,239	-	-	-
Cashflow From Investing	431.6%	24,274	4,566	17,275	4,395	-48,365	10,405	560	43,844	-14,859	-35,346	-80,241	19,177	14,503	-	-	-
Cashflow From Financing	124.4%	7,992	3,562	-8,234	891	65,305	6,307	-455	578	-98.00	404	120,547	10,247	6,144	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RXST Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Sales	$ 29,512	$ 17,489
Cost of sales	8,827	7,123
Gross profit	20,685	10,366
Operating expenses:
Selling, general and administrative	23,324	16,255
Research and development	8,031	7,208
Total operating expenses	31,355	23,463
Loss from operations	(10,670)	(13,097)
Other income (expense), net:
Interest expense	(6)	(1,507)
Interest and other income	1,585	1,392
Loss before income taxes	(9,091)	(13,212)
Income tax expense	9	0
Net loss	(9,100)	(13,212)
Other comprehensive income (loss)
Unrealized gain (loss)on short-term investments	(45)	84
Foreign currency translation gain (loss)	(3)	2
Total other comprehensive (loss) income	(48)	86
Comprehensive loss	$ (9,148)	$ (13,126)
Net loss per share:
Attributable to common stock, basic	$ (0.25)	$ (0.42)
Attributable to common stock, diluted	$ (0.25)	$ (0.42)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic	36,843,087	31,637,097
Attributable to common stock, diluted	36,843,087	31,637,097

RXST Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,645	$ 9,692
Short-term investments	92,709	117,490
Accounts receivable	21,550	20,281
Inventories, net	18,700	17,421
Prepaid and other current assets	2,955	3,523
Total current assets	168,559	168,407
Property and equipment, net	11,617	10,841
Operating leases right-of-use assets	2,052	2,444
Restricted cash	711	711
Other assets	226	147
Total assets	183,165	182,550
Current liabilities:
Accounts payable	5,057	3,863
Accrued expenses and other current liabilities	11,657	15,239
Lease liabilities	1,614	1,801
Total current liabilities	18,328	20,903
Long-term lease liabilities	908	1,211
Other long-term liabilities	0	74
Total liabilities	19,236	22,188
Commitments and contingencies (Note 9)
Stockholders' deficit:
Common stock, $0.001 par value, 900,000,000 shares authorized, 37,161,753 shares issued and outstanding as of March 31, 2024 and 36,139,513 shares issued and outstanding as of December 31, 2023	37	36
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	767,685	754,971
Accumulated other comprehensive loss	(53)	(5)
Accumulated deficit	(603,740)	(594,640)
Total stockholders' deficit	163,929	160,362
Total liabilities and stockholders' equity	$ 183,165	$ 182,550

About RxSight, Inc.

RxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

CEO	Dr. Ronald M. Kurtz M.D.
WEBSITE	rxsight.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	292

RxSight, Inc. Frequently Asked Questions

What is the ticker symbol for RxSight, Inc.? What does RXST stand for in stocks?

RXST is the stock ticker symbol of RxSight, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RxSight, Inc. (RXST)?

As of Fri May 17 2024, market cap of RxSight, Inc. is 2.26 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXST stock?

You can check RXST's fair value in chart for subscribers.

What is the fair value of RXST stock?

You can check RXST's fair value in chart for subscribers. The fair value of RxSight, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RxSight, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RXST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RxSight, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXST is over valued or under valued. Whether RxSight, Inc. is cheap or expensive depends on the assumptions which impact RxSight, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXST.

What is RxSight, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RXST's PE ratio (Price to Earnings) is -50.7 and Price to Sales (PS) ratio is 22.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXST PE ratio will change depending on the future growth rate expectations of investors.